Risankizumab-rzaa (Skyrizi IV)

Provider Order Form rev. 01/02/2024

| PATIENT INFORMATION | Referral Stat | :us: □ New R | eferral 🗆 Updated (| Order D Order Renewal | |
|--|--|---|---------------------|-----------------------|--|
| Patient Name: | | DOB: | Patient | | |
| Patient Address: Patient Email: | | | | | |
| Allergies: | | □ NKDA | Weight (lbs/kg): | Height (in/cm): | |
| Sex: □ M / □ F Date of Last Infusion: | Next Due [| | Preferred Location | | |
| | | | | ·· | |
| DIAGNOSIS (Please provide ICD-10 code in s | - | | | | |
| Crohn's Disease (This is the only diagnosis the I | V dosing is used for | ·): | | | |
| THERAPY ADMINISTRATION & DOSING ☑ Administer Risankizumab-rzaa (Skyrizi) 600mg IV over 1 hour Dilute in dextrose 5% 100ml (preferred) ☑ Only IV induction dosing will be provided. Subcutaneous dosing WILL NOT be provided FREQUENCY (Choose one) ☑ Induction: week 0, week 4, and week 8 ADDITIONAL ORDERS | | PRE-MEDICATION ORDERS ☐ Tylenol ☐ 500mg / ☐ 650mg PO ☐ Loratadine 10mg PO ☐ Pepcid 20mg ☐ PO / ☐ IVP ☐ Benadryl ☐ 25mg / ☐ 50mg ☐ PO / ☐ IVP ☐ Solumedrol ☐ 40mg / ☐ 125mg IVP ☐ Other: NURSING ☑ Hold infusion and notify provider for: | | | |
| Required Documentation: Patient demos, copy | y of front and back of munosuppressants, | Preferred Contact Email: Provider NPI: Phone: Fax: City: State: Zip Code: (Additional documentation required for processing and insurance approval) front and back of primary and secondary insurance, 2 most recent OVN includinosuppressants, biologic agent and steroids, Colonoscopy | | | |
| TO THE DESTRUCTION OF THE PROPERTY OF THE PROP | m dom, | | | | |
| Provider Name (print) | Provider Signature | | | Date | |